Close
  Indian J Med Microbiol
 

Figure 2: (a) Means plot of comparison of mean number of adverse events following immunization among different age groups. The mean number of adverse events following immunization among the vaccinees aged <30 years was 1.49 ± 0.761, 30–59 years was 1.46 ± 0.724 and ≥60 years was 1.29 ± 0.469. On comparison of mean number of adverse events following immunization between three different age groups F = 0.564 and P = 0.569. (n = 422, data expressed as mean ± standard deviation). (b) Means plot of comparison of mean duration of adverse events following immunization among different age groups. The mean duration of adverse event following immunization (in days) among vaccinees aged <30 years was 2.50 ± 0.761, 30–59 years was 2.59 ± 1.020, and ≥60 years was 2.29 ± 0.726. On comparison of mean duration of adverse event following immunization between three different age groups F = 1.216 and P = 0.298. (n = 422, data expressed as mean ± standard deviation)

Figure 2: (a)  Means plot of comparison of mean number of adverse events following immunization among different age groups. The mean number of adverse events following immunization among the vaccinees aged <30 years was 1.49 ± 0.761, 30–59 years was 1.46 ± 0.724 and ≥60 years was 1.29 ± 0.469. On comparison of mean number of adverse events following immunization between three different age groups <i>F</i> = 0.564 and <i>P</i> = 0.569. (<i>n</i> = 422, data expressed as mean ± standard deviation). (b) Means plot of comparison of mean duration of adverse events following immunization among different age groups. The mean duration of adverse event following immunization (in days) among vaccinees aged <30 years was 2.50 ± 0.761, 30–59 years was 2.59 ± 1.020, and ≥60 years was 2.29 ± 0.726. On comparison of mean duration of adverse event following immunization between three different age groups <i>F</i> = 1.216 and <i>P</i> = 0.298. (<i>n</i> = 422, data expressed as mean ± standard deviation)